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Proper protein folding is essential for normal 
immunoglobulin synthesis and secretion in anti­
body­secreting plasma cells (PCs). The mam­
malian unfolded protein response (UPR) is a 
signaling pathway that responds to ER stress 
that is induced by the accumulation of unfolded 
proteins  within  the  ER  lumen  (Todd  et  al., 
2008). Inositol­requiring transmembrane ki­
nase/endonuclease 1 (IRE1) is an ER­localized 
transmembrane protein that senses unfolded 
proteins and serves to activate X­box binding 
protein 1 (XBP1), a member of the CREB/
ATF basic leucine zipper family of transcription 
factors and a crucial mediator of one branch of 
the UPR (Yoshida et al., 2001; Calfon et al., 
2002; Lee et al., 2002). IRE1 possesses endo­
ribonuclease activity that excises a 26­nt sequence 
from XBP1 messenger RNA (mRNA). This 
event, termed XBP1 splicing, shifts the reading 
frame to excise a premature stop codon, resulting 
in a full­length functional XBP1 protein prod­
uct (Yoshida et al., 2001; Calfon et al., 2002; 
Lee et al., 2002). XBP1 then translocates to the 
nucleus where it induces target genes involved 
in protein synthesis and secretion (Shaffer et al., 
2004; Lee et al., 2005).
XBP1 activation is crucial to the normal 
function and survival of highly secretory cells 
such as exocrine gland acinar cells and Paneth 
cells (Kaser et al., 2008). Using XBP1/RAG2/ 
lymphoid  chimeric  mice,  we  have  shown 
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The unfolded protein response (UPR) is a stress response pathway that is driven by the 
increased load of unfolded proteins in the endoplasmic reticulum of highly secretory cells 
such as plasma cells (PCs). X box binding protein 1 (XBP1) is a transcription factor that 
mediates one branch of the UPR and is crucial for the development of antibody-secreting 
PCs. PCs represent only one class of terminally differentiated B cells, however, and little is 
known about the role for XBP1 in the other class: memory B cells. We have developed an 
XBP1fl/fl CD19+/cre conditional knockout (XBP1CD19) mouse to build upon our current under-
standing of the function of XBP1 in PC differentiation as well as to explore the role of 
XBP1 in memory cell development. Using this model, we show that XBP1CD19 mice are 
protected from disease in an autoantibody-mediated mouse lupus model. We also identify a 
novel developmental stage at which B cells express the traditional PC marker CD138 (syn-
decan-1) but have yet to undergo XBP1-dependent functional and morphological differen-
tiation into antibody-secreting cells. Finally, we show that memory B cells develop normally 
in XBP1CD19 mice, demonstrating that XBP1-mediated functions occur independently of any 
memory cell lineage commitment.
© 2009 Todd et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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in cell surface expression of IgM and IgD between XBP1CD19 
and XBP1+/+ splenocytes (Fig. S1 B). In accord with the 
known function of XBP1 in PC development, basal Ig levels 
were markedly reduced in XBP1CD19 mice (Fig. S1 C). Fur­
thermore, these mice exhibited impaired Ig responses to the 
T cell–dependent antigen nitrophenol (NP)­KLH upon pri­
mary or secondary stimulation (Fig. S2, A and B, respec­
tively). A similar defect was observed in mice immunized 
with the T cell–independent antigen NP­ficoll (Fig. S2 C).
XBP1 up­regulates the expression of UPR­related target 
genes that function collectively in protein synthesis and se­
cretion. XBP1 targets include the ER­associated degradation 
protein EDEM, ER­localized chaperones like ER­localized 
Dnajb9 (ERdj4), the ER translocon component Sec61, and 
proteins, such as protein disulfide isomerase (PDI), that aid 
disulfide bond formation (Todd et al., 2008). Using B220+ 
splenocytes isolated from XBP1CD19 and XBP1+/+ mice, we 
next measured the expression of XBP1 target genes in these 
B cells after culture for 0–3 d in the presence or absence of   
10 µg/ml LPS (Fig. S3 A). As expected, quantitative PCR 
analysis demonstrated that, by day 3 of culture, there were 
significant increases in the expression of the aforementioned 
XBP1 target genes in XBP1+/+ B cells. These same target 
genes were up­regulated to a lesser degree or not at all in 
XBP1CD19 B cells. In addition, XBP1CD19 B cells did not 
demonstrate an appropriate up­regulation of S, which nor­
mally allows for newly synthesized IgM to be secreted.   
Importantly, B cells from XBP1CD19 and XBP1+/+ mice showed 
no difference in their modest increase in expression of Ig 
heavy chain binding protein (BiP), another UPR related 
gene which is not directly downstream of XBP1.
XBP1 deletion did not affect B cell proliferation or viabil­
ity in response to LPS treatment. Both were comparable be­
tween XBP1CD19 and XBP1+/+ B cells as measured by exclusion 
of 7­amino­actinomycin D (7­AAD) and annexin V (Fig. S3 B) 
or by exclusion of trypan blue (Fig. S3 C). In contrast, XBP1 
deletion led to markedly reduced secretion of IgM by LPS­
stimulated XBP1CD19 B cells (Fig. S3 D). Collectively, these 
data demonstrate that XBP1 deletion leads to defects in the 
UPR that impair normal synthesis and secretion of immuno­
globulin without affecting B cell viability or proliferative prop­
erties. Importantly, these initial experiments in XBP1CD19 mice 
recapitulated the known roles of XBP1 in PC development 
and  function,  as  has  been  shown  previously  using  XBP1/
RAG2/ lymphoid chimeric mice (Reimold et al., 2001).
We next investigated the impact of XBP1 deficiency on 
the broader network of transcriptional regulators that direct 
PC differentiation (for review see Calame et al., 2003). The 
transcription factors Bcl­6 (B cell lymphoma 6) and paired 
box gene 5 (Pax5) repress B lymphocyte–induced maturation 
protein 1 (Blimp1) and IFN regulatory factor 4 (IRF4), re­
spectively, and promote B cell proliferation and the GC reac­
tion. On the contrary, Blimp1 and IRF4 normally arrest cell 
cycle progression and the GC reaction to promote and sus­
tain PC development (Calame et al., 2003). Furthermore, 
Blimp1 and IRF4 permit the expression of XBP1 (Shaffer   
previously that XBP1 expression is required for normal PC 
development and function as well (Reimold et al., 2001). 
Chimeric  mice  demonstrated  markedly  reduced  serum  Ig 
levels and impaired Ig response to immunization. This defect 
was the result of a failure of cells to up­regulate UPR­related 
XBP1 target genes during terminal B cell differentiation 
(Iwakoshi et al., 2003; Shaffer et al., 2004). The requirement 
of XBP1 for PC differentiation raises the possibility that dis­
ruption of XBP1 activity may represent a potential therapeu­
tic target for the treatment of autoimmune diseases, such as 
systemic lupus erythematosus (SLE), in which autoantibodies 
may be directly pathogenic.
Little is known about the role of XBP1 in the develop­
ment and function of another important B cell population: 
memory B cells. These B cells have been exposed to antigen, 
undergo a germinal center (GC) reaction, and function to 
differentiate rapidly into antibody­secreting B cells after   
reexposure to cognate antigen (for review see McHeyzer­ 
Williams and McHeyzer­Williams, 2005). They do not express 
CD138 (syndecan­1), a cell surface glycoprotein which has 
traditionally  been  used  a  marker  for  Ig­secreting  PCs   
(Sanderson and Børset, 2002). Memory B cells also function 
to replete the pool of long­lived antibody­secreting PCs (for 
review see McHeyzer­Williams and McHeyzer­Williams, 2005), 
which may represent a persistent source of autoantibodies 
(Neubert et al., 2008).
The recent development of a XBP1flox conditional KO 
(cKO) mouse (Hetz et al., 2008) has prompted us to explore 
further the function of XBP1 in terminal B cell development. 
CD19 expression is limited to B cells and occurs in pro–B 
cells and throughout the remaining stages of B cell develop­
ment (Zhou et al., 1991; Hardy and Hayakawa, 2001). We 
therefore bred the XBP1flox cKO mouse to a mouse express­
ing cre recombinase under the control of CD19 promoter 
to delete XBP1 selectively from B cells (Rickert et al., 1997). 
In the current series of experiments, we use XBP1flox/flox 
CD19cre/+ (XBP1CD19) cKO mice first to confirm the func­
tional PC defects in XBP1/RAG2/ lymphoid chimeric 
mice (Reimold et al., 2001). In addition, we now report that   
XBP1CD19 mice were protected from mouse lupus. We also 
show, unexpectedly, that the number of cells with the tradi­
tional B220int CD138+ PC phenotype is normal in XBP1CD19 
mice as compared with XBP1flox/flox CD19+/+ (XBP1+/+) 
controls. Finally, we report that XBP1CD19 mice have normal 
populations of memory B cells, demonstrating that this alter­
native differentiation pathway for B cells is not dependent on 
the XBP1 branch of the UPR.
RESULTS AND DISCUSSION
Initial characterization of XBP1CD19 cKO mice
To determine the efficiency of XBP1 deletion in the B cells 
in XBP1CD19 mice, splenocytes from these mice were isolated 
and separated into B220+ and B220 populations using mag­
netic beads coupled to an anti­B220 mAb. Southern blotting 
demonstrated efficient and specific deletion of XBP1 in the 
B220+ (B cell) fraction (Fig. S1 A). There were no differences JEM VOL. 206, September 28, 2009  2153
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When  treated  with  bortezomib,  these  lupus­prone  mice 
lacked autoantibodies, were devoid of mature PCs, and were 
protected from mouse lupus. Proteasome inhibitors suppress 
ER­associated  degradation  pathways  such  that  misfolded 
proteins accumulate in cells, cause ER stress, and induce the 
UPR  (Obeng  et  al.,  2006).  Chronic  ER  stress,  however, 
causes cell cycle arrest and cellular apoptosis (Zinszner et al., 
1998; Brewer and Diehl, 2000). Proteasome inhibitors like 
et al., 2004; Klein et al., 2006). For Blimp1, this regulatory 
event  is  accomplished  by  Blimp1­mediated  repression  of 
Pax5, which derepresses XBP1 to ensure an appropriate UPR 
in anticipation of Ig production and secretion (Shaffer et al., 
2004). Despite the failure to differentiate into Ig­secreting 
PCs, LPS­stimulated XBP1CD19 B cells displayed a typical PC 
signature of these transcription factors: down­regulation of 
Pax5 and up­regulation of Blimp1 and IRF4 mRNAs. Inter­
estingly, Blimp1 and IRF4 were substantially overexpressed 
in LPS­stimulated XBP1CD19 B cells compared with XBP1+/+ 
controls (Fig. S3 A). These data suggest that XBP1 deletion 
did not alter the genetic program of PC development. Fur­
thermore, failure to up­regulate Ig secretion in the absence of 
XBP1 appears to promote the PC developmental program, 
supporting the hypothesis that a mechanism of feedback inhi­
bition exists whereby XBP1 down­regulates Blimp1 and IRF4 
expression in LPS­stimulated B cells (Hu et al., 2009).
Mice with XBP1-deficient B cells are protected  
from mouse lupus
BALB/c mice develop anti–double­stranded DNA (dsDNA) 
autoantibodies and immune complex deposits in glomeruli 
when immunized with a DNA mimotope, the decapeptide 
DWEYSVWLSN on a polylysine backbone (MAP­DWEYS; 
Putterman and Diamond, 1998). Furthermore, when treated 
with LPS to disrupt the blood brain barrier, MAP­DWEYS–
immunized mice develop lesions in the hippocampus of the 
brain, a process which is attributable to excitatory cell death 
induced by stimulatory autoantibodies bound to neuronal 
N­methyl­d­aspartic acid (NMDA) receptors (Kowal et al., 
2004).  Anti­NMDA  receptor  autoantibodies  have  also  been 
identified in the cerebrospinal fluid of humans with SLE, and this 
mouse system has been used as a model of human central nervous 
system lupus (DeGiorgio et al., 2001; Kowal et al., 2006).
We next sought to use this mouse model of SLE to test 
whether XBP1CD19 mice were capable of developing auto­
antibodies and associated pathological findings of mouse lupus. 
XBP1CD19 and litter­matched XBP1+/+ mice were immu­
nized with MAP­DWEYS three times over a 1­mo period, 
as described in Materials and methods. Serum anti­peptide 
and anti­dsDNA antibodies were readily detected in XBP1+/+ 
control mice but were only weakly present in XBP1CD19 
mice (Fig. 1, A and B). These same mice were then treated 
with 3 mg/kg LPS and killed 4–7 d later for immunohisto­
chemistry (IHC) analysis of kidney and brain (Fig. 1 C). IHC 
revealed abundant IgG in glomeruli of five out of five control 
mice and in the hippocampus of two out of five controls, but 
none was present in any of the XBP1CD19 mouse tissues. Thus, 
mice with B cells deficient in XBP1 were protected from 
autoantibody production and disease expression in this mouse 
model of SLE.
This observation is reminiscent of a recent compelling 
study in which two lupus­prone mouse strains (NZB/W F1 and 
MRL/lpr) were treated with bortezomib, a selective inhibi­
tor of the 26S proteosome which is used therapeutically to 
treat human myeloma, a PC malignancy (Neubert et al., 2008).   
Figure 1.  Female XBP1+/+ and XBP1CD19 mice were immunized i.p. 
with 100 µg MAP-DWEYS in CFA followed by booster immuniza-
tions with 100 µg MAP-DWEYS in IFA on days 14 and 28.  
(A and B) On day 35, serum was tested for anti-DWEYS (peptide; A) and 
anti-dsDNA (B) antibodies by ELISA of four serum dilutions. In both pan-
els, each circle represents the mean ± SEM value for XBP1+/+ (closed cir-
cles) or XBP1CD19 (open circles) mice. (C) XBP1+/+ and XBP1CD19 mice from 
A and B were treated i.p. with 3 mg/kg LPS on days 52 and +54. Shown 
are representative images of IgG-specific IHC of kidney (top) and hippo-
campus (bottom) of mice 4–7 d after LPS treatment. XBP1+/+ mice dem-
onstrated anti-IgG binding to neurons in the CA1 region of the 
hippocampus. There was no anti-IgG binding in any of the XBP1CD19 ani-
mals. Bars: (kidney) 200 µm; (hippocampus) 100 µm. All panels represent 
results from a single experiment with five mice per group. A second inde-
pendent experiment reproduced these findings (not depicted).2154 XBP1 AND TERMINAL B CELL DIFFERENTIATION | Todd et al.
arrest. This occurs before achieving normal PC morphology 
and functional activity because of a failure to up­regulate 
XBP1­dependent UPR target genes. CD138 is a member of 
the syndecan family of heparin sulfate proteoglycans and is 
comprised  of  a  transmembrane  core  protein  covalently 
bonded  to  heparin  sulfate  moieties  (Sanderson  and  Yang, 
2008). CD138 also exists as part of the bone marrow stroma 
and in a soluble form that may be shed from cell membranes. 
Cell  surface–bound  CD138  impairs  invasion  of  myeloma 
cells through collagen gels (Liebersbach and Sanderson, 
1994), facilitates cell–cell aggregation (Stanley et al., 1995), 
and promotes myeloma adhesion to collagen in the extracel­
lular matrix (Ridley et al., 1993). These functions have been 
hypothesized  to  explain  the  organ  selectivity  of  myeloma 
bortezomib are toxic to myeloma cells, in part through   
targeting the activity of IRE1 (Lee et al., 2003; Obeng et al., 
2006). These findings raise the intriguing notion that inhibi­
tion of XBP1 or the UPR in general may represent a poten­
tial therapeutic target in the treatment of autoantibody­mediated 
diseases like SLE.
The developmental defect in XBP1-deficient PCs occurs 
after CD138 expression
XBP1CD19 mice allow us to explore further the developmen­
tal stage at which PC differentiation arrests. Complicating 
this analysis, however, is the observation that PCs down­
regulate many B cell surface markers such as B220, CD19, 
and CD20 (Hardy and Hayakawa, 2001). Traditionally, cell 
surface expression of CD138 by B cells has been viewed as 
a marker for antibody­secreting PCs (B220int CD138+ cells; 
Sanderson and Børset, 2002). Accordingly, we immunized 
XBP1CD19 and XBP1+/+ mice with NP­KLH to measure the 
distribution of B220 and CD138 staining over time. Surpris­
ingly, even though XBP1CD19 mice had markedly impaired 
Ig responses to immunization (Fig. S2), both XBP1CD19 and 
XBP1+/+ mice had comparable numbers of B220int CD138+ 
splenocytes (Fig. 2 A). In XBP1CD19 mice, these cells lacked 
the expanded ER and perinuclear cuff of Golgi found in 
normal  PCs  (Fig.  2  B).  This  difference  was  quantifiable; 
B220int  CD138+  cells  from  XBP1CD19  mice  demonstrated   
less intensive staining by brefeldin A boron­dipyrromethane 
(BODIPY),  which  selectively  binds  to  secretory  ER  and 
Golgi content (Fig. 2 C) (Hetz et al., 2008).
5  d  after  NP­KLH  immunization,  splenocytes  from 
XBP1CD19 and XBP1+/+ mice were isolated and FACS sorted 
into B220int CD138+ and B220+ CD138 cell populations, 
from which RNA was purified for quantitative PCR analy­
sis. In accord with what is known about PCs, B220int CD138+ 
cells from XBP1+/+ mice expressed much greater levels of the 
XBP1 target genes ERdj4, EDEM, PDI, and Sec61 as com­
pared with B220+ CD138 cells from the same mice (Fig. 3). 
There were also increased levels of BiP, S, Blimp1, and 
IRF4 and reduced levels of Pax5. These differences were also 
observed, but to a much lesser degree, in the two sorted 
XBP1CD19 B cell populations. When comparing B220int CD138+ 
cells from XBP1CD19 and XBP1+/+ mice, XBP1 target genes 
and S were reduced in expression in cKO cells, and levels 
of BiP and Pax5 were similar. Unlike what was observed in 
LPS­stimulated B cells, however, levels of Blimp1 and IRF4 
were not elevated in cells from XBP1CD19 mice. This sup­
ports the hypothesis that there are multiple pathways of B cell 
differentiation depending on the specific exogenous stimulus. 
Indeed, in vitro LPS­stimulated B cells behave differently 
than in vivo immunogen­stimulated B cells, and this is likely 
caused, in part, by the absence of T helper cell activity as well 
as by the different activation pathways involved (for review 
see McHeyzer­Williams and McHeyzer­Williams, 2005).
Collectively, our data show that XBP1CD19 B cells can 
survive and differentiate to the developmental stage at which 
they express CD138, at which point they developmentally 
Figure 2.  XBP1+/+ and XBP1CD19 mice were immunized i.p. with a 
single 100-µg dose of NP-KLH in alum. (A) Representative flow cy-
tometry of cell surface CD138 (y axis) and B220 (x axis) expression in 
splenocytes isolated from XBP1+/+ and XBP1CD19 mice at days 0, 5, and 14 
after immunization. Mean percentage ± SEM of B220int CD138+ cells is 
indicated. (B) B220int CD138+ cells were isolated by FACS from a subset of 
splenocytes at day 5 after immunization. Cytospin preparations of cells 
were stained with modified Wright-Giemsa stain. (C) Splenocytes were 
isolated from mice on day 5 after immunization and incubated with 
Brefeldin A BODIPY, which selectively stains ER and Golgi organelles. 
Shown are representative flow cytometry histograms for B220int CD138+ 
cells (solid line), B220+ CD138 cells (long dashed line), and unstained 
cells (short dashed line). Brefeldin A-BODIPY mean fluorescence intensity 
(MFI) ± SEM is indicated for B220int CD138+ cells (no difference in B220+ 
CD138 cells). All experiments were performed with individual mice in at 
least three independent experiments.JEM VOL. 206, September 28, 2009  2155
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which is then followed by XBP1­directed UPR transcrip­
tional events and large­scale immunoglobulin secretion. This 
differs from our previously published results in which CD138 
was not detected on the surface of XBP1­deficient B cells 9 d 
after immunization with 2,4­dinitrophenyl (DNP)­albumin 
in XBP1/RAG2/ lymphoid chimeric mice (Reimold et al., 
2001). One limitation of the XBP1/RAG2/ lymphoid chi­
meric model, however, is that it cannot ascribe this difference 
solely to an intrinsic deficiency of XBP1 in B cells. With the 
recent discovery that XBP1 is important for the normal devel­
opment and function of dendritic cells (Iwakoshi et al., 2007), 
one could conjecture that XBP1 function in non–B cell pop­
ulations might in part explain the reduced numbers of CD138+ 
cells in the chimeric mice. Thus, the XBP1CD19 cKO system 
provides some refinement in our understanding of the rela­
tionship between XBP1 and CD138 expression.
Post-GC memory cells and preplasma memory cells are 
intact in mice with B cells that lack XBP1
Memory B cells make up the second major population of 
terminally differentiated B cells (for review see McHeyzer­
Williams and McHeyzer­Williams, 2005). They are long­
lived antigen­specific cells that reside mainly in peripheral 
cells, and CD138 is being investigated as a potential thera­
peutic target in myeloma (Sanderson and Yang, 2008).
The role of CD138 in normal PCs, however, is less well 
defined, although it may have similar bone marrow homing 
functions in PCs as in myeloma cells. CD138 is expressed   
on the cell surface of PCs and bone marrow–resident B cell   
precursors. It is not present on the surface of mature naive   
B cells in the bone marrow, circulation, or secondary lym­
phoid organs (Sanderson et al., 1989). CD138 expression has   
been closely correlated with Ig secretion (Lalor et al., 1992), 
and CD138+ plasmablasts have been previously described   
(Angelin­Duclos et al., 2000), but the existence of a non– 
  Ig­secreting CD138+ cell population has not been formally 
demonstrated until now. The converse has been seen, how­
ever, in that Blimp1­deficient B cells do not express CD138 
but can secrete small amounts of Ig (Shapiro­Shelef et al., 
2003; Kallies et al., 2007). However, this represents an earlier 
(initial)  developmental  stage  of  PC  differentiation  in  that 
these cells are unable to attain the large secretory capabilities 
or phenotype of mature PCs (Kallies et al., 2007). IRF4­
  deficient B cells also fail to express CD138 (Klein et al., 2006).
Our findings therefore indicate that in developing PCs, 
Blimp1  and  IRF4  expression  precedes  CD138  expression, 
Figure 3.  XBP1+/+ and XBP1CD19 mice were immunized i.p. with a single 100-µg dose of NP-KLH in alum. At day 5 after immunization, spleno-
cytes were isolated and sorted by FACS for B220+ CD138 (B220) and B220int CD138+ (CD138) populations. Panels show relative expression of indicated 
mRNA versus actin as measured by RT-PCR of cDNA prepared from indicated cell populations. In all panels, each bar represents the mean ± SEM value of 
individual XBP1+/+ (open bar) and XBP1CD19 (solid bar) mice in three independent experiments.2156 XBP1 AND TERMINAL B CELL DIFFERENTIATION | Todd et al.
cess. Neither Blimp1 nor IRF4 are required for the develop­
ment of post­GC memory B cells (Shapiro­Shelef et al., 
2003; Klein et al., 2006). Blimp1­deficient B cells, however, 
fail to differentiate into preplasma memory B cells (Shapiro­
Shelef et al., 2003). Furthermore, IRF4­deficient post­GC   
B cells can expand upon reencounter with cognate antigen   
(a memory cell–driven response), but they fail to differentiate 
into PCs (Klein et al., 2006). Thus, neither of these transcrip­
tion  factors  appears  to  be  crucial  for  development  of  the 
memory B cell population de novo.
tissues, including in the lung, gut, and peripheral lymphoid 
organs. When reexposed to cognate antigen, memory B cells 
proliferate, and a subset differentiates into antibody­secreting 
PCs.  Memory  B  cell  subpopulations  can  be  distinguished 
phenotypically as post­GC B cells (B220+ CD138) or pre­
plasma memory B cells (B220 CD79b+ CD138; for review 
see McHeyzer­Williams and McHeyzer­Williams, 2005).
Little is known about the transcriptional programs that 
regulate B cell differentiation into memory cells, including 
whether there is any role for XBP1 or the UPR in this pro­
Figure 4.  Memory B cells are present in normal numbers in XBP1CD19 mice. (A, left) Representative expression of IgD and NP on [PI, CD4, CD8, 
F4/80, GR1]neg splenocytes of day-14 mice immunized with Ribi (adjuvant) only (left) or NP-KLH in Ribi (right). Shown are XBP1fl/fl CD19+/+ (XBP1+/+) mice 
(top) and XBP1fl/fl CD19cre/+ (XBP1CD19) littermates (bottom). The inset represents the percentage of cells within profile (mean ± SEM; n = 3). (A, right) Total 
number of IgDlo NP-specific B cells from day 0 (naive BALB/c), adjuvant only (day 14 Ribi only), day 5, and day 14 NP-KLH in Ribi immunized XBP1+/+ mice 
(white columns) and XBP1CD19 (black columns) mice (mean ± SEM; n = 3). (B, left) Representative expression of B220 and CD138 at the surface of IgDlo 
NP-specific B cells at days 5 (left) and 14 (right) from XBP1+/+ mice (top) and XBP1CD19 littermates (bottom). The inset represents the percentage of cells 
within profile (mean ± SEM; n = 3). (B, right) Total number of NP-specific B cells compartment B220+, CD79b+ B220lo, or CD138+ at day 5 (top) or day 14 
(bottom) immunized XBP1+/+ (white columns) and XBP1CD19 (black columns) mice (mean ± SEM; n = 3; unpaired Student’s t test; P > 0.05 for all data 
points). (C) [PI, CD4, CD8, F4/80, GR1]neg IgDlo NP+ CD138+ splenocytes of day-5 and day-14 immunized mice were sorted directly ex vivo into NP-specific 
Ig (IgM or IgG) revealing ELISPOT assays. Positives were scored manually under a dissection microscope. Each assay was done in triplicate from three sep-
arate animals (mean ± SEM; n = 3; unpaired Student’s t test; *, P ≤ 0.05).JEM VOL. 206, September 28, 2009  2157
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are solely the result of a failure of formation of antibody­
  secreting PCs and not of B cell memory itself.
Summary
Collectively, this analysis of B cells from XBP1CD19 cKO 
mice expands our understanding of the crucial role of XBP1 
in terminal B cell development as it pertains to PC develop­
ment, autoantibody­mediated autoimmune disease, and memory 
cell development. Deletion of XBP1 leads to failed up­regu­
lation of the UPR in developing PCs with subsequent defi­
ciencies in antibody responses to antigen. Interestingly, the 
experiments presented here identify and characterize a pre­
viously unrecognized population of antibody hyposecreting 
B220int CD138+ B cells in XBP1CD19 mice, demonstrating 
that XBP1­mediated UPR events occur after the develop­
mental stage at which CD138 is expressed. Importantly, we 
establish that memory B cell populations are unaffected by 
XBP1 deficiency such that XBP1­related activity can be situ­
ated independent of the memory B cell lineage commitment. 
Finally, XBP1CD19 mice are protected from autoantibody­
mediated mouse lupus. This has therapeutic implications from 
a clinical perspective in that inhibition of XBP1 or the UPR 
in general potentially represents a therapeutic target in the 
treatment of SLE.
MATERIALS AND METHODS
Mice and immunization. The creation of XBP1flox mice harboring loxP 
sites in the first and second intron of the XBP1 gene has been described pre­
viously (Hetz et al., 2008; Kaser et al., 2008; Lee et al., 2008). These mice 
were backcrossed 10 generations with BALB/c mice, which was the back­
ground strain for all experiments described in these studies. XBP1flox/flox mice 
were bred to CD19cre/+ BALB/c mice that express cre recombinase under 
the control of the CD19 promoter (The Jackson Laboratory; Rickert et al., 
1997).  Two  generations  of  breeding  yielded  XBP1CD19  cKO  mice  and 
XBP1+/+ control mice. All mice were born in Mendelian ratios and devel­
oped normally. Wild­type BALB/c mice were purchased from Taconic. 
Experimental protocols were approved by the Standing Committee on Ani­
mals at the Harvard Medical School and were designed with institutional and 
National Institutes of Health guidelines for the humane use of animals.
To measure serum antibody responses to immunization, 6–8­wk­old 
XBP1CD19 and XBP1+/+ mice were injected i.p. with 100 µg NP­KLH (Bio­
search Technologies) emulsified in alum (Thermo Fisher Scientific) or 25 µg 
NP­ficoll (Biosearch Technologies). Blood was collected from mice via retro­
orbital bleed at the time of immunization and weekly for 2 wk. To measure 
secondary serum antibody responses, some mice that had received NP­KLH 
were reimmunized with 100 µg NP­KLH in alum 8 wk after primary immu­
nization, and additional blood samples were obtained at the time of reimmu­
nization and weekly for 2 wk. For NP­specific B cell studies, 8–14­wk­old 
mice were immunized subcutaneously with 400 µg NP­KLH in Ribi adju­
vant (laboratory formulation based on Baldridge and Crane [1999]).
B cell isolation and culture. Single cell suspensions of splenocytes were 
prepared from 6–8­wk­old mice, and erythrocytes were removed by os­
motic  lysis  with  NH4Cl  buffer  (Sigma­Aldrich)  as  previously  described   
(Iwakoshi et al., 2003). Splenic B cells were purified using B220+ magnetic 
bead selection (Miltenyi Biotech) and confirmed to have >90% purity by 
flow cytometry for cell surface CD19 expression. For some B cell prepara­
tions, Southern blotting was used to determine efficacy of XBP1 deletion in 
B220+ lymphocytes. The remaining B220+ splenocytes from XBP1CD19 and 
XBP1+/+ mice were cultured at 106 cells/ml for 0–3 d in the presence or ab­
sence  of  10  µg/ml  LPS  (Sigma­Aldrich)  in  complete  media  containing 
We  have  already  demonstrated  that  secondary  Ig  re­
sponses are markedly blunted in XBP1CD19 mice (Fig. S2). 
Using a well established protocol to study memory B cells 
(Shapiro­Shelef et al., 2003), we next sought to answer 
whether  the  defect  in  secondary  memory  responses  in   
XBP1CD19 mice is solely attributable to impaired antibody se­
cretion by PCs or whether there may also be independent 
deficiencies in memory B cell populations themselves. Mice 
were immunized with 400 µg NP­KLH in Ribi adjuvant and 
splenocytes were isolated at day 5 or 14. Cells were stained 
with antibodies specific for CD4, CD8, F4/80 (a macrophage 
marker), GR1 (a granulocyte and monocyte marker), B220 
(CD45R), CD138, IgD, GL7, CD38, and Ig  light chain. In 
addition, cells were stained with propidium iodide (PI) to 
determine viability and allophycocyanin (APC)­conjugated 
NP to identify antigen­specific B cells. Viable post­GC NP­
specific B cells were identified as those cells that excluded PI, 
were [CD4, CD8, F4/80, GR1]neg, and demonstrated a 
NP+IgDlo phenotype. The expansion of these cells after im­
munization was comparable between XBP1CD19 and XBP1+/+ 
mice (Fig. 4 A).
These NP­specific B cells were further assayed for ex­
pression of B220 and CD138 to identify B220+ CD138 
post­GC memory cells, B220lo CD79b+ CD138 preplasma 
memory cells, and B220int CD138+ cells with a PC pheno­
type (Fig. 4 B). At day 5 after immunization, there were no 
differences in the relative or absolute numbers of the subpop­
ulations between XBP1CD19 and XBP1+/+ mice. At day 14, 
there were some differences in the relative numbers of these 
cells, but the absolute numbers were not significantly differ­
ent because the number of splenocytes and absolute number 
of NP­specific cells were up to twofold greater in XBP1CD19 
mice. There were no differences in the total number of antigen­
specific GC versus post­GC events at day 14 as measured   
by  CD138neg  GL7hi  CD38lo  GC  B  cells  versus  CD138neg 
GL7lo CD38hi post­GC B cells (Fig. S4 A). There were also 
no differences between XBP1CD19 and XBP1+/+ mice when 
assayed for the repertoire of  light chain expression by anti­
gen­specific B cells (Fig. S4 B). ELISPOT was used to mea­
sure the ability of FACS­purified B220int CD138+ cells to 
secrete IgM and IgG. At days 5 and 14, the number of NP­
specific IgG­secreting B cells was significantly reduced in 
XBP1CD19 mice as compared with controls (Fig. 4 C). Similar 
results were obtained for NP­specific IgM­secreting cells at 
day 5 but not at day 14. These assays reinforce the notion that 
XBP1CD19 B cells are able to differentiate into B220int CD138+ 
cells but lack the normal capacity for Ig secretion.
Thus, XBP1CD19 B cells are capable of differentiating nor­
mally into post­GC or preplasma memory B cell populations. 
These  observations  again  place  XBP1­mediated  events 
downstream of Blimp1, which is crucial for the development 
of preplasma memory B cell (Shapiro­Shelef et al., 2003). 
These data also show for the first time that the XBP1­driven 
branch of the UPR is unnecessary for the development of 
memory B cells themselves. Thus, the defects in Ig produc­
tion during secondary antigen challenge in XBP1CD19 mice 2158 XBP1 AND TERMINAL B CELL DIFFERENTIATION | Todd et al.
RNA using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). Quantitative real­time PCR reactions using SYBR green fluo­
rescent reagent were run in an Mx3005P system (Agilent Technologies) and 
analyzed as previously described (Iwakoshi et al., 2007). Primer sequences 
are listed in Table S1.
Mouse lupus. Using an established model of mouse lupus (Kowal et al., 
2004), 6–8­wk­old XBP1CD19 and XBP1+/+ mice were immunized i.p. with 
100 µg MAP­DWEYS emulsified in CFA (Sigma­Aldrich). Booster immu­
nizations with 100 µg MAP­DWEYS in IFA (Sigma­Aldrich) were given on 
days 14 and 28. Serum was obtained from these mice on day 35 and tested 
for anti­peptide and anti­dsDNA antibodies as previously described (Kowal 
et al., 2004). There were five mice per group. To disrupt the blood brain 
barrier in the hippocampus, mice were given i.p. injections of 3 mg/kg LPS 
(Escherichia coli, 055:B5; Sigma­Aldrich) on days 52 and 54. Mice were then 
killed 4–7 d after LPS treatment to analyze tissues for histological evidence 
of mouse SLE. After cardiac perfusion, brains and kidneys were isolated and 
tissues were immunostained for IgG as previously described (Putterman and 
Diamond, 1998; Kowal et al., 2004).
Online supplemental material. Table S1 lists primer sequences used for 
quantitative real­time PCR. Fig. S1 shows XBP1 deletion and basal immuno­
globulin production in XBP1CD19 mice. Fig. S2 shows immunoglobulin 
production in immunized XBP1CD19 mice. Fig. S3 shows in vitro analysis of 
XBP1­deficient B cells. Fig. S4 shows additional characterization of memory 
cells in XBP1CD19 mice. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20090738/DC1.
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